Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



EC Healthcare

醫思健康

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2138)

INSIDE INFORMATION SALES VOLUME UPDATE

This announcement is made by EC Healthcare (the "Company", together with its subsidiaries, the "Group") pursuant to Rule 13.09 of The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules") and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the laws of Hong Kong).

SALES VOLUME FOR THE YEAR ENDED 31 MARCH 2023

The Board wishes to inform the shareholders of the Company (the "Shareholders") and potential investors that based on the latest assessment by the Board with reference to the preliminary unaudited management accounts of the Group for the year ended 31 March 2023 (the "Period") currently available, the Group's sales volume (being the total sales volume generated from contracted sales entered into, and all products and services offered by the Group, the "Sales Volume") is summarized as below:

Year-on-Year growth during the Period	1 st Half	2 nd Half	Full Year
Overall Sales Volume	Increase by 21%+	Increase by 27%+	Increase by 24%+
Sales Volume of medical services	Increase by 36%+	Increase by 41%+	Increase by 39%+
Sales Volume of aesthetic medical and wellness services in Hong Kong & Macau	Decrease by 9%-	Increase by 18%+	Increase by 4%+
Sales Volume of aesthetic medical and wellness services in Mainland China	Decrease by 15%-	Decrease by 34%-	Decrease by 25%-
Sales Volume of other services	Increase by 95%+	Increase by 4%+	Increase by 36%+

Note: (+) refers to no less than, (-) refers to no more than

The Group expects to record:

- (i) overall Sales Volume of no less than HK\$3,800 million for the Period, representing an increase of no less than 24% as compared with the same period last year; and
- (ii) an increase in Sales Volume of medical services offered by the Group of no less than 39% for the

Period as compared with the same period last year; and

- (iii) an increase in Sales Volume of aesthetic medical and beauty and wellness services located in Hong Kong and Macau offered by the Group of no less than 4% for the Period as compared with the same period last year;
- (iv) a decrease in Sales Volume of aesthetic medical and beauty and wellness services located in Mainland China offered by the Group of no more than 25% for the Period as compared with the same period last year; and
- (v) an increase in Sales Volume of other services offered by the Group of no less than 36% for the Period as compared with the same period last year.

The Board believes that the decrease in aesthetic medical and beauty and wellness services in Mainland China during the Period was mainly due to (i) recurrent outbreaks of the COVID-19 in Mainland China; (ii) the strict pandemic prevention policies implemented by the government; and (iii) the social distancing measures in many provinces of Mainland China.

Normal travel between Hong Kong and Mainland China was partially resumed from 8 January 2023 and has been fully resumed on 6 February 2023. The Hong Kong government reported approximately 0.3 million, 1.1 million and 2.0 million tourist visits from Mainland China in January 2023, February 2023 and March 2023, respectively. Benefiting from the return of Mainland tourists, the Group's Sales Volume contributed by Mainland visitors in Hong Kong during January to March in 2023 was approximately HK\$82 million. We expect the return of Mainland visitors to continue at a gradual pace with an ongoing positive impact on our performance in Hong Kong.

The Board wishes to remind Shareholders and potential investors that the above data are based on the unaudited management accounts of the Group which have not been reviewed or audited by the auditors of the Company. Sales performance during the financial year are affected by a series of factors, and the operational data disclosed in this announcement may not be able to reflect the overall performance of the Group for a complete financial year.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board EC Healthcare Raymond Siu Company Secretary

Hong Kong, 28 April 2023

As at the date of this announcement, the executive Directors of the Company are Mr. Tang Chi Fai, Mr. Lu Lyn Wade Leslie, Mr. Lee Heung Wing, Ms. Wong Ka Ki Ada, and Mr. Wong Chi Cheung; the non-executive Director is Mr. Luk Kun Shing Ben; and the independent non-executive Directors are Mr. Ma Ching Nam, Mr. Look Andrew and Mr. Au Tsun.